论文部分内容阅读
当1985年春,垂体的人体生长激素(HGH)在瑞典市场消失后,代之以生物合成制剂Somatonorm(一种Somatrem类制剂)。某些病人决定不再继续用重组合(recombinant)的HGH,而多数采用Somatonorm。在1985年12月,此药已在瑞典被允许注册。目前,大约有180名患者应用此药,其中130名曾接受过垂体的HGH治疗,其余的曾采用重组体的HGH(Crescormon)。绝大多数患者每日行皮下注射,每周剂量为0.5～0.8IU/kg。Somato-
When the human body growth hormone (HGH) in the pituitary gland disappeared in the Swedish market in the spring of 1985, it was replaced by the biosynthetic preparation Somatonorm (a form of Somatrem). Some patients decided not to continue to use recombined HGH, and most used Somatonorm. In December 1985, the drug was allowed to register in Sweden. At present, about 180 patients have applied the drug, of which 130 have received pituitary HGH treatment, and the rest have used recombinant HGH (Crescormon). The vast majority of patients received daily subcutaneous injections at weekly doses of 0.5 to 0.8 IU/kg. Somato-